End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.99 CNY | -0.18% |
|
-1.96% | -18.55% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.55% | 1.78B | - | ||
+63.05% | 854B | C+ | ||
+39.42% | 636B | B | ||
-4.78% | 361B | C+ | ||
+17.52% | 324B | B- | ||
+8.43% | 301B | C+ | ||
+14.19% | 247B | B+ | ||
+5.81% | 230B | A+ | ||
+16.77% | 228B | B- | ||
+14.63% | 177B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600422 Stock
- Ratings KPC Pharmaceuticals,Inc.